The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
WOOD Grand Rapids on MSN4d
Nose spray to treat depression? FDA approves first-of-its-kind medicineThe U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...
Hosted on MSN6d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback